Vetoquinol SA banner

Vetoquinol SA
PAR:VETO

Watchlist Manager
Vetoquinol SA Logo
Vetoquinol SA
PAR:VETO
Watchlist
Price: 87 EUR 1.64% Market Closed
Market Cap: €1B

Net Margin

11.3%
Current
Improving
by 0.8%
vs 3-y average of 10.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.3%
=
Net Income
€60.1m
/
Revenue
€532.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11.3%
=
Net Income
€60.1m
/
Revenue
€532.4m

Peer Comparison

Country Company Market Cap Net
Margin
FR
Vetoquinol SA
PAR:VETO
1B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
997.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
578.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
281.1B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
303.5B USD
Loading...
CH
Novartis AG
SIX:NOVN
230.9B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.1B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
154.7B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD
Loading...

Market Distribution

Higher than 81% of companies in France
Percentile
81th
Based on 2 398 companies
81th percentile
11.3%
Low
-147 400% — -2.2%
Typical Range
-2.2% — 7.1%
High
7.1% — 14 243.8%
Distribution Statistics
France
Min -147 400%
30th Percentile -2.2%
Median 2.6%
70th Percentile 7.1%
Max 14 243.8%

Vetoquinol SA
Glance View

Market Cap
1B EUR
Industry
Pharmaceuticals

Vétoquinol SA operates as a global animal health company. The company is headquartered in Lure, Bourgogne-Franche-Comte. The company went IPO on 2006-11-16. The Company’s product portfolio is divided between livestock, such as cattle and pigs, and companion animals, including dogs and cats. Vetoquinol SA’s offering includes anti-infectives, such as Marbocyl; anti- pain inflammatories, which comprise Tolfedine, intended for dogs and cats, and Tolfine for livestock, and cardiovascular and nephrology treatment, such as Prilium, an oral daily administration formula for dogs, among others. The firm markets over 700 products, in such countries as France, Austria, Canada, Italy, Poland, Spain and the Netherlands, among others. The company trades its products throughout Europe, North America, Africa, the Middle East and Pacific Asia. In April 2014, it acquired Bioniche's animal health business.

VETO Intrinsic Value
68.9 EUR
Overvaluation 21%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
11.3%
=
Net Income
€60.1m
/
Revenue
€532.4m
What is Vetoquinol SA's current Net Margin?

The current Net Margin for Vetoquinol SA is 11.3%, which is above its 3-year median of 10.5%.

How has Net Margin changed over time?

Over the last 3 years, Vetoquinol SA’s Net Margin has increased from 9% to 11.3%. During this period, it reached a low of 8.8% on Jun 30, 2024 and a high of 11.3% on Jun 30, 2025.

Back to Top